Americas
Worldwide
Japan
Asia Pacific
Americas
Europe, Middle East, and Africa
Mizuho Bank
Mizuho Trust & Banking
Mizuho Securities
Search
Who We Are
Our People
Diversity & Inclusion
Awards
Locations
Events
What We Do
Banking
Overview
Industry Coverage
Consumer + Retail
Energy
Financial Institutions
Financial Sponsors
Healthcare
Industrials
Power + Utilities + Infrastructure
Real Estate
Technology + Media + Telecom
Corporate Banking
Debt Capital Markets
Equity Capital Markets
Leveraged Finance
Mergers & Acquisitions
Private Capital Advisory
Mizuho | Greenhill International Presence
Regional Coverage
Restructuring
Risk Solutions
Banking Insights
Markets
Overview
Equities
Fixed Income
Futures + Options
Research
Overview
Corporate & Institutional Services
Overview
Treasury Services
Overview
Commercial Card
Deposits
Cash Management
Insights + News
Insights
News
Press Releases
Sustainability
Sustainability
Community
Foundation
Media Relations
Press Releases-
Media Contacts & Resources-
Careers
Client Login
Futures-
US Equity Research-
Japan Equity Research-
Global Custody-
Commercial Card Portal-
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho’s Jared Holz
January 24, 2025
Jared Holz, Mizuho, joins ‘Fast Money’ to talk Novo Nordisk’s recent climb.
Share This
Latest Mizuho News
See all news
Prefer Novo short-term as a GLP-1 play, says Mizuho’s Jared Holz
April 20, 2026
Iran war highlights risks in the chemical supply chain
April 15, 2026
Wall Street jumps to near one-month highs after US-Iran ceasefire
April 8, 2026
Mizuho news from around the globe
Mizuho Global News
back-to-top-blue
